Skip to content
Search:
Search
Facebook page opens in new window
 
ADCS
Alzheimer's Disease Cooperative Study
ADCSADCS
  • About Us
    • About ADCS
    • Meet the Team
    • ADCS Cores
    • ADCS Site Network
    • ADCS Steering Committee
    • Publications
  • Participate in Research
  • Public Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Types of Studies
    • Lifestyle Interventions
    • Alzheimer’s Study Quilt Project
    • DONATE
  • Investigator Resources
    • Study Resources
    • Data Sharing
    • Biorepository
    • ADCS Instruments
    • Intervention Selection Committee (ISC)
    • Preliminary Proposals
    • Combination Therapy Call OPEN
  • Epstein Family Alzheimer’s Research Collaboration
  • About Us
    • About ADCS
    • Meet the Team
    • ADCS Cores
    • ADCS Site Network
    • ADCS Steering Committee
    • Publications
  • Participate in Research
  • Public Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Types of Studies
    • Lifestyle Interventions
    • Alzheimer’s Study Quilt Project
    • DONATE
  • Investigator Resources
    • Study Resources
    • Data Sharing
    • Biorepository
    • ADCS Instruments
    • Intervention Selection Committee (ISC)
    • Preliminary Proposals
    • Combination Therapy Call OPEN
  • Epstein Family Alzheimer’s Research Collaboration

Monthly Archives: September 2014

You are here:
  1. Home
  2. 2014
  3. September

A new study published in the British Medical Journal finds that anti-anxiety drugs may increase the risk of Alzheimer’s.

Research NewsBy ADCS AdminSeptember 10, 2014

The drugs have been associated with short-term cognitive impairment, but the connection to Alzheimer’s has been less clear. Now, the new study finds a convincing, and apparently strong, link between benzodiazepines and Alzheimer’s disease.

New study using transgenic mice suggests how caffeine may protect the brain from Alzheimer’s.

Research NewsBy ADCS AdminSeptember 5, 2014

Epidemiologic evidences support that habitual caffeine intake prevents memory decline during aging and reduces the risk to develop Alzheimer’s disease. So far, experimental studies addressed the impact of caffeine in models mimicking the amyloid pathology of AD. However, in vivo effects of caffeine in a model of AD-like tauopathy remain unknown.

Copyright 2017 Regents of the University of California.
Go to Top